The reiteration of a Buy rating and maintenance of an $11 price target by HC Wainwright & Co. analyst Vernon Bernardino is a positive signal for Candel Therapeutics. This indicates that the analyst continues to have confidence in the company's prospects, which could lead to increased investor interest and a potential short-term positive impact on the stock price.